PMCK Berhad – Undervalued Small-Cap Play on Northern Malaysia’s Private Healthcare Boom

PMCK Berhad is strategically positioned to capture underserved demand for private healthcare services in northern Malaysia, driven by macroeconomic tailwinds, an ageing population, and rising insurance penetration. With a fair value of RM0.26, the stock offers compelling upside potential based on small-cap healthcare sector valuation metrics.

1️⃣ Expansion into High-Growth Region: PMC Kulim to Double Capacity

• PMCK is developing a 12-storey, 90-bed private medical centre in Kulim, Kedah, targeting 1QCY2028 commencement.

• The new facility consolidates operations and expands PMCK’s footprint in a region with limited private healthcare capacity (only 7.72 beds per 10,000 population, vs. 17.71 in Kuala Lumpur).

• Target market includes elderly-rich states: Kedah (9.1% elderly), Perlis (8.2%), and Penang (8.0%) — all above national average.

• Offers significant room to grow from current 121 operational beds, already representing 24.2% of Kedah’s private market.

2️⃣ Sustainable Model with Long-Term Operating Leverage

• PMCK operates a robust, repeat-driven model with an 84.8% repeat patient rate (FPE25).

• Diversified across 17 medical specialisations and backed by a strong team of experienced consultants.

• Poised to benefit from Ministry of Health’s HSOP initiative through outsourced services (e.g., radiology, cardiology, nephrology), helping alleviate public healthcare bottlenecks.

• Potential for margin expansion through higher utilisation of beds, equipment, and medical staff.

3️⃣ Insurance Adoption Tailwind and Strong Payer Network

• Private medical insurance claims in Malaysia reached RM8.9 billion in 2024, with a CAGR of 12.5%, reflecting rising adoption and better affordability.

• PMCK’s corporate client relationships with insurers (AIA, Zurich, Great Eastern) create a stable revenue basevia employee benefit-linked contracts.

• TPA reimbursement model enhances cash flow predictability and reduces receivables risk versus self-paying patients.

• Plans to roll out premium outpatient offerings (e.g., IVF, wellness) to capitalise on higher-margin service segments.

Valuation and Peer Comparison

• Target Price: RM0.26

• Based on: FY26F EPS of 1.4 sen

• Implied P/E: 18x — in line with small-cap healthcare peers on Bursa with similar regional footprint and service scale.

Peer Benchmarks:

Company	Market Cap	P/E (Fwd)	Remarks
KPJ Healthcare	Large-Cap	~28x	National leader, urban focus
Optimax Holdings	Small-Cap	~22x	Niche (ophthalmology)
PMCK Berhad	Small-Cap	18x (TP)	Underserved northern growth play

Catalysts to Watch

• PMC Kulim construction milestones (2025–2028)

• MOH outsourcing contracts under HSOP

• Rollout of higher-margin specialist services (e.g., IVF)

• Increase in corporate panel coverage and TPA networks

• Sector rerating on healthcare demand post-tariff uncertainty

Risks

• Construction delay or cost overruns at PMC Kulim

• Regulatory changes in private healthcare licensing

• Rising operating costs in medical personnel and equipment

• Policy shifts in medical insurance coverage or TPA agreements

Conclusion

PMCK Berhad is a well-managed regional healthcare provider expanding into a structurally underpenetrated region. Supported by demographic tailwinds and healthcare reforms, the Group’s earnings visibility and scalability position it as an attractive small-cap play. We believe its RM0.26 fair value reflects its growth trajectory and is supported by sector multiples.